CollaGenex Pharmaceuticals announces award of ADA Seal of Acceptance for Periostat
CollaGenex Pharmaceuticals, Inc. announced June 26 that Periostat�, its systemic therapy for the adjunctive treatment of adult periodontitis, had been awarded the ADA Seal of Acceptance by the American Dental Association.
The ADA stated, "Periostat has been shown to help stop the progression of periodontitis when used as directed as an adjunct to scaling and root planing, in a conscientiously applied program of oral hygiene and regular professional care.'' - Council on Scientific Affairs, American Dental Association.
"Obtaining the ADA Seal is a further confirmation of the safety and efficacy of Periostat,'' noted Brian M. Gallagher, PhD, chairman, president and chief executive officer of CollaGenex. "It is particularly exciting to receive this acceptance from the ADA, who undertakes a rigorous review, from a clinical perspective, of the safety and efficacy data supporting a new product prior to granting the Seal. This review process assembles opinions from a team of professional dental consultants as well as a panel of scientific council members, including academicians and practicing dentists.''
"Periostat is the first, and only, oral, systemic prescription drug for the treatment of adult periodontitis which has been granted the ADA Seal of Acceptance,'' concluded Gallagher.
CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental market. The Company's lead product, Periostat, was approved by the FDA in September 1998 and is the first and only pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues.
In February 2001, the FDA granted marketing approval for a new tablet formulation for Periostat. Periostat is marketed to the dental community by CollaGenex through a professional pharmaceutical sales force composed of approximately 120 sales representatives and managers.
